Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and Dyslipidemia in morbidly obese patients who present for Bariatric surgery

Rouzbeh Mostaedi, Denise E. Lackey, Sean H. Adams, Stephen A. Dada, Zahid A. Hoda, Mohamed R Ali

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Pharmacotherapy is considered the primary treatment modality for diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (DYS). We sought to investigate the status of DM, HTN, and DYS in patients who seek bariatric surgery. Methods: Demographic and comorbidity history were prospectively collected on 1,508 patients referred for bariatric consultation at a single institution from February 2008 to March 2012. We utilized published consensus guidelines (GL) to benchmark the efficacy of standard pharmacotherapy for these metabolic diseases, and 881 patients met the study design criteria. Results: Most patients exhibited at least one form of metabolic dysregulation (pre-DM or DM, 75.8 %; pre-HTN or HTN, 91.1 %; pre-DYS or DYS, 84.0 %; metabolic syndrome, 76.0 %). The majority of patients either did not meet GL treatment goals (DM, 45.7 %; HTN, 39.5 %; DYS, 22.3 %) or were previously undiagnosed (DM, 15.8 %; HTN, 13.7 %; DYS, 41.7 %). Non-GL pharmacotherapy was significantly less effective than GL pharmacotherapy at achieving treatment goals for DM (31.8 vs 53.2 %, p < 0.001) and HTN (43.6 vs 63.2 %, p = 0.007). Patients with concurrent DM, HTN, and DYS (35.5 %) were less likely than patients with only one or two of these metabolic diseases to achieve GL treatment goals for HTN (38.1 vs 72.6 %, p < 0.001) and DYS (55.7 vs 73.8 %, p = 0.002). Only 8.0 % of these patients achieved treatment goals for all three metabolic comorbidities. Conclusions: In this patient group, DM, HTN, and DYS were poorly compensated, even when pharmacotherapy was consistent with published GL. This may be due to disease burden in bariatric surgery candidates or to inadequate medical management prior to presentation.

Original languageEnglish (US)
Pages (from-to)927-935
Number of pages9
JournalObesity Surgery
Volume24
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Bariatric Surgery
Dyslipidemias
Type 2 Diabetes Mellitus
Diabetes Mellitus
Hypertension
Guidelines
Drug Therapy
Metabolic Diseases
Comorbidity
Prehypertension
Bariatrics
Therapeutics
Benchmarking
Referral and Consultation
History
Demography

Keywords

  • Bariatric surgery
  • Comorbidities
  • Diabetes mellitus
  • Dyslipidemia
  • Hypertension
  • Metabolic syndrome
  • Obesity
  • Pharmacotherapy

ASJC Scopus subject areas

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and Dyslipidemia in morbidly obese patients who present for Bariatric surgery. / Mostaedi, Rouzbeh; Lackey, Denise E.; Adams, Sean H.; Dada, Stephen A.; Hoda, Zahid A.; Ali, Mohamed R.

In: Obesity Surgery, Vol. 24, No. 6, 2014, p. 927-935.

Research output: Contribution to journalArticle

Mostaedi, Rouzbeh ; Lackey, Denise E. ; Adams, Sean H. ; Dada, Stephen A. ; Hoda, Zahid A. ; Ali, Mohamed R. / Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and Dyslipidemia in morbidly obese patients who present for Bariatric surgery. In: Obesity Surgery. 2014 ; Vol. 24, No. 6. pp. 927-935.
@article{81c4e08073f0441cad8b5a5bde2eb9bf,
title = "Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and Dyslipidemia in morbidly obese patients who present for Bariatric surgery",
abstract = "Background: Pharmacotherapy is considered the primary treatment modality for diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (DYS). We sought to investigate the status of DM, HTN, and DYS in patients who seek bariatric surgery. Methods: Demographic and comorbidity history were prospectively collected on 1,508 patients referred for bariatric consultation at a single institution from February 2008 to March 2012. We utilized published consensus guidelines (GL) to benchmark the efficacy of standard pharmacotherapy for these metabolic diseases, and 881 patients met the study design criteria. Results: Most patients exhibited at least one form of metabolic dysregulation (pre-DM or DM, 75.8 {\%}; pre-HTN or HTN, 91.1 {\%}; pre-DYS or DYS, 84.0 {\%}; metabolic syndrome, 76.0 {\%}). The majority of patients either did not meet GL treatment goals (DM, 45.7 {\%}; HTN, 39.5 {\%}; DYS, 22.3 {\%}) or were previously undiagnosed (DM, 15.8 {\%}; HTN, 13.7 {\%}; DYS, 41.7 {\%}). Non-GL pharmacotherapy was significantly less effective than GL pharmacotherapy at achieving treatment goals for DM (31.8 vs 53.2 {\%}, p < 0.001) and HTN (43.6 vs 63.2 {\%}, p = 0.007). Patients with concurrent DM, HTN, and DYS (35.5 {\%}) were less likely than patients with only one or two of these metabolic diseases to achieve GL treatment goals for HTN (38.1 vs 72.6 {\%}, p < 0.001) and DYS (55.7 vs 73.8 {\%}, p = 0.002). Only 8.0 {\%} of these patients achieved treatment goals for all three metabolic comorbidities. Conclusions: In this patient group, DM, HTN, and DYS were poorly compensated, even when pharmacotherapy was consistent with published GL. This may be due to disease burden in bariatric surgery candidates or to inadequate medical management prior to presentation.",
keywords = "Bariatric surgery, Comorbidities, Diabetes mellitus, Dyslipidemia, Hypertension, Metabolic syndrome, Obesity, Pharmacotherapy",
author = "Rouzbeh Mostaedi and Lackey, {Denise E.} and Adams, {Sean H.} and Dada, {Stephen A.} and Hoda, {Zahid A.} and Ali, {Mohamed R}",
year = "2014",
doi = "10.1007/s11695-014-1196-z",
language = "English (US)",
volume = "24",
pages = "927--935",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and Dyslipidemia in morbidly obese patients who present for Bariatric surgery

AU - Mostaedi, Rouzbeh

AU - Lackey, Denise E.

AU - Adams, Sean H.

AU - Dada, Stephen A.

AU - Hoda, Zahid A.

AU - Ali, Mohamed R

PY - 2014

Y1 - 2014

N2 - Background: Pharmacotherapy is considered the primary treatment modality for diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (DYS). We sought to investigate the status of DM, HTN, and DYS in patients who seek bariatric surgery. Methods: Demographic and comorbidity history were prospectively collected on 1,508 patients referred for bariatric consultation at a single institution from February 2008 to March 2012. We utilized published consensus guidelines (GL) to benchmark the efficacy of standard pharmacotherapy for these metabolic diseases, and 881 patients met the study design criteria. Results: Most patients exhibited at least one form of metabolic dysregulation (pre-DM or DM, 75.8 %; pre-HTN or HTN, 91.1 %; pre-DYS or DYS, 84.0 %; metabolic syndrome, 76.0 %). The majority of patients either did not meet GL treatment goals (DM, 45.7 %; HTN, 39.5 %; DYS, 22.3 %) or were previously undiagnosed (DM, 15.8 %; HTN, 13.7 %; DYS, 41.7 %). Non-GL pharmacotherapy was significantly less effective than GL pharmacotherapy at achieving treatment goals for DM (31.8 vs 53.2 %, p < 0.001) and HTN (43.6 vs 63.2 %, p = 0.007). Patients with concurrent DM, HTN, and DYS (35.5 %) were less likely than patients with only one or two of these metabolic diseases to achieve GL treatment goals for HTN (38.1 vs 72.6 %, p < 0.001) and DYS (55.7 vs 73.8 %, p = 0.002). Only 8.0 % of these patients achieved treatment goals for all three metabolic comorbidities. Conclusions: In this patient group, DM, HTN, and DYS were poorly compensated, even when pharmacotherapy was consistent with published GL. This may be due to disease burden in bariatric surgery candidates or to inadequate medical management prior to presentation.

AB - Background: Pharmacotherapy is considered the primary treatment modality for diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (DYS). We sought to investigate the status of DM, HTN, and DYS in patients who seek bariatric surgery. Methods: Demographic and comorbidity history were prospectively collected on 1,508 patients referred for bariatric consultation at a single institution from February 2008 to March 2012. We utilized published consensus guidelines (GL) to benchmark the efficacy of standard pharmacotherapy for these metabolic diseases, and 881 patients met the study design criteria. Results: Most patients exhibited at least one form of metabolic dysregulation (pre-DM or DM, 75.8 %; pre-HTN or HTN, 91.1 %; pre-DYS or DYS, 84.0 %; metabolic syndrome, 76.0 %). The majority of patients either did not meet GL treatment goals (DM, 45.7 %; HTN, 39.5 %; DYS, 22.3 %) or were previously undiagnosed (DM, 15.8 %; HTN, 13.7 %; DYS, 41.7 %). Non-GL pharmacotherapy was significantly less effective than GL pharmacotherapy at achieving treatment goals for DM (31.8 vs 53.2 %, p < 0.001) and HTN (43.6 vs 63.2 %, p = 0.007). Patients with concurrent DM, HTN, and DYS (35.5 %) were less likely than patients with only one or two of these metabolic diseases to achieve GL treatment goals for HTN (38.1 vs 72.6 %, p < 0.001) and DYS (55.7 vs 73.8 %, p = 0.002). Only 8.0 % of these patients achieved treatment goals for all three metabolic comorbidities. Conclusions: In this patient group, DM, HTN, and DYS were poorly compensated, even when pharmacotherapy was consistent with published GL. This may be due to disease burden in bariatric surgery candidates or to inadequate medical management prior to presentation.

KW - Bariatric surgery

KW - Comorbidities

KW - Diabetes mellitus

KW - Dyslipidemia

KW - Hypertension

KW - Metabolic syndrome

KW - Obesity

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84901483396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901483396&partnerID=8YFLogxK

U2 - 10.1007/s11695-014-1196-z

DO - 10.1007/s11695-014-1196-z

M3 - Article

VL - 24

SP - 927

EP - 935

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - 6

ER -